NEWS
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") today announced publication of a landmark study titled, "Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer's Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Studyi" in the Journal of Alzheimer's Disease. This study builds on recent findings from Nexalin's Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer's disease (AD).
This new research involved 46 patients, randomly assigned to receive either real DIFS or sham treatment for 30 one-hour sessions over a period of three weeks. Resting-state functional magnetic resonance imaging (rs-fMRI) was used to track changes in brain activity, showing that Nexalin's proprietary DIFS technology significantly alters neuronal activity in key regions of the brain, providing a non-pharmacological, safe treatment option for Alzheimer's.
This new research involved 46 patients, randomly assigned to receive either real DIFS or sham treatment for 30 one-hour sessions over a period of three weeks. Resting-state functional magnetic resonance imaging (rs-fMRI) was used to track changes in brain activity, showing that Nexalin's proprietary DIFS technology significantly alters neuronal activity in key regions of the brain, providing a non-pharmacological, safe treatment option for Alzheimer's.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2541Followers
107Following
28KVisitors
Follow